The American Journal of Surgery
Volume 197, Issue 3 , Pages 302-307 , March 2009

Early colectomy may be associated with improved survival in fulminant Clostridium difficile colitis: an 8-year experience

  • Christopher W. Seder, M.D.

      Affiliations

    • Department of Surgery, Division of Infectious Diseases, William Beaumont Hospitals, Royal Oak, MI 48073, USA
    • ,
  • Mario R. Villalba Jr., M.D.

      Affiliations

    • Department of Surgery, Division of Infectious Diseases, William Beaumont Hospitals, Royal Oak, MI 48073, USA
    • ,
  • James Robbins, M.D.

      Affiliations

    • Department of Surgery, Division of Infectious Diseases, William Beaumont Hospitals, Royal Oak, MI 48073, USA
    • ,
  • Felicia A. Ivascu, M.D.

      Affiliations

    • Department of Surgery, Division of Infectious Diseases, William Beaumont Hospitals, Royal Oak, MI 48073, USA
    • ,
  • Christopher F. Carpenter, M.D.

      Affiliations

    • Department of Internal Medicine, Division of Infectious Diseases, William Beaumont Hospitals, Royal Oak, MI 48073, USA
    • ,
  • Mary Dietrich, B.S.N.

      Affiliations

    • Department of Epidemiology, William Beaumont Hospitals, Royal Oak, MI 48073, USA
    • ,
  • Mario R. Villalba Sr., M.D.

      Affiliations

    • Department of Surgery, Division of Infectious Diseases, William Beaumont Hospitals, Royal Oak, MI 48073, USA
    • Corresponding Author InformationCorresponding author. Tel.: +01-248-288-1130; fax: +01-248-288-5931

Received 22 August 2008 ,Revised 8 November 2008

References 

  1. Barbut F, Corthier G, Charpak Y, et al. Prevalence and pathogenicity of Clostridium difficile in hospitalized patients: a French multicenter study. Arch Intern Med. 1996;156:1449–1454
  2. Weir E, Flegel K. Protecting against Clostridium difficile illness. CMAJ. 2005;172:1178
  3. Spencer RC. The role of antimicrobial agents in the aetiology of Clostridium difficile associated disease. J Antimicrob Chemother. 1998;41:C21–C27
  4. Carignan A, Allard C, Pepin J, et al. Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin Infect Dis. 2008;46:1838–1843
  5. Pepin J, Valiquette L, Chouinard D. Clostridium difficile-associated diarrhea in a region of Quebec from 1991–2003: a changing pattern if disease severity. JAMC. 2004;5:466–470
  6. Dallal RM, Harbrecht BG, Simmons RL. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complication. Ann Surg. 2002;235:363–372
  7. Synnott K, Mealy K, Merry C, et al. Timing of surgery for fulminating pseudomembranous colitis. Br J Surg. 1998;85:229–231
  8. Eggertson LC. Difficile may have killed 2,000 in Quebec: study. CMAJ. 2005;173:1020–1021
  9. McEllistrem MC, Carman RJ, Gerding DN, et al. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis. 2005;40:265–272
  10. Health Protection Agency. Outbreak of Clostridium difficile infection in a hospital in south east England. Commun Dis Rep CDR Wkly. 2005;15:2–3http://www.hpa.org.uk/cdr/archives/2005/cdr2405.pdfAccessed: June 3, 2008
  11. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442–2449
  12. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079–1084
  13. Byrn JC, Maun DC, Gingold DS, et al. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg. 2008;143:150–154
  14. Gerasymchuk L, Swami A, Carpenter CF, et al. Clostridium difficile associated disease (CDAD) in Michigan: an analysis for the presence of the epidemic strain and its relationship to severity of disease at an academic tertiary care hospital and affiliated extended care facilities (ECFs). Presented at the 45th Annual Infectious Diseases Society of America Meeting, San Diego, CA, October 6 to7, 2007.
  15. Longo WE, Mazuski JE, Virgo KS, et al. Outcome after colectomy for Clostridium difficile colitis. Dis Colon Rectum. 2004;47:1620–1626
  16. Medich DS, Lee KK, Simmons RL, et al. Laparotomy for fulminant pseudomembranous colitis. Arch Surg. 1992;127:847–853
  17. Koss K, Clark MA, Sanders DS, et al. The outcomes of surgery in fulminant Clostridium difficile colitis. Colorectal Dis. 2006;8:149–154
  18. Kyne L, Concepta M, O'Neill D. Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing. 1998;28:107–113
  19. McFarland LV. Epidemiology, risk factors and treatments for antibiotic associated diarrhea. Digest Dis. 1998;16:292–307
  20. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998;40:1–15
  21. Bartlett JG, Chang TW, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin producing Clostridia. N Engl J Med. 1978;298:531–534
  22. Bricker E, Garg R, Nelson R, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev. 2005;CD004610
  23. Buchner AM, Sonnenberg A. Medical diagnoses and procedures associated with Clostridium difficile colitis. Am J Gastroenterol. 2001;96:766–772
  24. Rubin MS, Bodenstein LE, Kent KC, et al. Difficile colitis. Dis Colon Rectum. 1998;38:350–354
  25. Prendergast TM, Marini CP, D'Angelo AJ, et al. Surgical patients with pseudomembranous colitis: factors affecting prognosis. Surgery. 1994;116:768–775
  26. Brown E, Talbot GH, Axelrod P. Risk factors for Clostridium difficile toxin associated diarrhea. Infect Control Hosp Epidemiol. 1990;11:283–290
  27. Kamanthan AG, Bruckner HW, Hirschman SZ. Clostridium difficile diarrhea induced by chemotherapy. Arch Intern Med. 1992;152:1715–1717
  28. Cudmore MA, Silva J, Fekety R. Clostridium difficile colitis associated with cancer chemotherapy. Arch Intern Med. 1982;142:333–335
  29. Trevisani F, Simoncini M, Alampi G. Colitis associated to chemotherapy with 5-fluorouracil. Hepatol Gastroenterol. 1997;44:710–712
  30. Kelly C. Immune response to Clostridium difficile infection. Eur J Gastroenterol Hepatol. 1996;8:1048–1053
  31. Kyne L, Warny M, Qamar A. Asymptomatic carriage of Clostridium difficile, serum level of IgG antibody against toxin A. N Engl J Med. 2000;342:390–397
  32. McFarland LV, Elmer GW, Stamm WE, et al. Correlation of immunoblot type, enterotoxin production, and cytotoxin production with clinical manifestations of Clostridium difficile infection in a cohort of hospitalized patients. Infect Immun. 1991;59:2456–2462
  33. Tabaqchali S. Epidemiologic markers of Clostridium difficile. Rev Infect Dis. 1990;12(Suppl 2):S192
  34. George RH, Symonds JM, Dimock F, et al. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br Med J. 1978;1:695
  35. Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis. 1997;24:324

PII: S0002-9610(08)00774-5

doi: 10.1016/j.amjsurg.2008.11.001

The American Journal of Surgery
Volume 197, Issue 3 , Pages 302-307 , March 2009

Article Tools